Infectious Diseases and Vaccines
Infectious diseases account for a large proportion of deaths and disability worldwide1. Infectious diseases pose a significant and rising threat to humankind due to globalisation, population growth, increasing travel and climate change. Furthermore, many diseases are notorious for their ability to mutate and become resistant to treatment.
It is therefore more crucial than ever that we fight to improve public health and to benefit patients worldwide.
At Janssen, our fight against infectious diseases is a global effort. From viral hepatitis and human immunodeficiency virus (HIV) to pathogens of global concern. We strive to discover and develop novel therapeutics and vaccines to help prevent, treat and utlimately cure infectious diseases worldwide, improving treatment outcomes and patients’ lives.
With goals like these, there’s no time to waste. That’s why the team focuses on internal discovery and world-class development of therapeutics and vaccines whilst seeking out partnerships across the world to connect our expertise with others. We believe these problems can be conquered the same way all of humanity’s greatest problems have been solved: persistent effort and game-changing innovation.
HIV is a virus spread through certain bodily fluids that attacks the body’s immune system, specifically the CD4 cells, often called T cells. Over time, HIV can destroy so many of these cells that the body can no longer fight off infections and disease. HIV remains one of the greatest global health challenges of our time; it is estimated that 36.9 million people are currently living with HIV globally, with at least 1.8 million more becoming newly infected each year 2.
Tuberculosis (TB) is caused by a bacterial infection, which most often affect the lungs. One-third of the world’s population is currently infected with the bacteria that cause TB, and anyone infected has a ten percent chance of suffering from TB during their lifetime 3. Although TB is curable and preventable, without proper treatment up to two thirds of people who develop active TB may die 3.
Respiratory Syncytial Virus (RSV) is a virus that can cause serious respiratory infections (infections of the lungs and airways) with symptoms ranging from a common cold to bronchiolitis and pneumonia (inflammation of the airways). RSV infection can occur at any age but is a particular threat during childhood 4.
Hepatitis B sometimes called Hep B or HBV, is a virus carried in the blood and bodily fluids which infects and damages the liver. Chronic hepatitis B infection is potentially life-threatening, putting people at high risk of cirrhosis and liver cancer. It is a major global health problem, and the most widespread form of hepatitis worldwide 5.
Pathogens of Global Concern we are dedicated to improving the health of humanity through research and collaborations which can enable a fast and efficient response to global health crises caused by outbreaks of pathogens such as Ebola, Zika and Dengue.
COVID-19 has had an unprecedented impact on the world as we know it. The Janssen Pharmaceutical Companies of Johnson & Johnson are committed to rapid scientific progress toward treatment and prevention measures for this global health crisis. Since January 2020, Johnson & Johnson has been working directly with Governments and health authorities to help end this fast-moving pandemic, and we will continue to bring our full resources and best scientific minds to combat it - not just because we can, because we must.
For more information on our response to COVID-19, please click here.
1. WHO. World Health Report
2. HIV.Gov. Statistics for HIV
3. WHO. Tuberculosis Fact Sheet,
4. Oxford Vaccine Group. What is Respiratory Syncytial Virus?
5. British Liver Trust. Hepatitis B.